The broader market weakness spread into the biotech sector in the week ending Jan. 28, sending stocks lower. Johnson & Johnson got the ball rolling on large-cap biopharma earnings, with mixed results. The positive forward outlook, however, lent support to the stock. Edwards Lifesciences Corporation came under pressure following an earnings miss. Among other noteworthy developments, the Pfizer-BioNTech SE alliance and Moderna Inc. separately commenced their omicron-specific COVID-19 vaccine studies. Gilead Sciences Inc. faced a setback after the Food and Drug Administration placed its clinical trials involving magrolimab on hold. Magrolimab, an anti-CD47 antibody, was acquired as part of the company’s $4.9 billion deal to buy Forty Seven Inc. The antibody treatment is being evaluated with azacytidine in five blood cancer studies, including three Phase 3 studies. Here are the key catalysts that could impact stocks in the unfolding week. Clinical Readouts/Presentations Athersys Inc. is scheduled to host a webcast on …